Watch Presentation:
Prescription Drug Affordability Boards: The Potential Impact on Patients

Prescription Drug Affordability Boards: The Potential Impact on Patients

In this edition of the Navigating Market Access with Magnolia webinar series, the Magnolia Market Access team explored the expanding role of Prescription Drug Affordability Boards (PDABs) and their growing impact on healthcare stakeholders. With more states enacting PDAB legislation, it is critical for manufacturers, providers, payers, and advocacy groups to understand how PDAB processes work, what drugs may be subject to affordability reviews, and how upper payment limits (UPLs) could alter access and reimbursement.

Key topics included:

  • The structure, function, and goals of PDABs
  • Overview of state legislation and PDAB authority
  • Detailed PDAB process flow from drug selection to affordability review and UPL determination
  • State-specific examples from Colorado, Maryland, and Oregon
  • Potential implications for pharmaceutical manufacturers, providers, payers, pharmacies, and patients
  • Opportunities for stakeholder engagement and awareness

Panelists include: